Gregory M. Weinhoff Sells 10,000 Shares of Centessa Pharmaceuticals plc (NASDAQ:CNTA) Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 10,000 shares of the company’s stock in a transaction that occurred on Monday, November 25th. The stock was sold at an average price of $17.66, for a total value of $176,600.00. Following the completion of the sale, the insider now owns 183,266 shares in the company, valued at approximately $3,236,477.56. This represents a 5.17 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this link.

Centessa Pharmaceuticals Price Performance

CNTA stock opened at $17.60 on Thursday. Centessa Pharmaceuticals plc has a 1 year low of $5.58 and a 1 year high of $18.74. The company has a debt-to-equity ratio of 0.15, a current ratio of 21.52 and a quick ratio of 21.52. The firm has a market capitalization of $2.32 billion, a PE ratio of -11.50 and a beta of 1.47. The business has a 50 day simple moving average of $16.13 and a 200-day simple moving average of $12.53.

Centessa Pharmaceuticals (NASDAQ:CNTA) last issued its earnings results on Tuesday, November 12th. The company reported ($0.37) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.05. Equities research analysts anticipate that Centessa Pharmaceuticals plc will post -1.6 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Centessa Pharmaceuticals

Several institutional investors and hedge funds have recently bought and sold shares of CNTA. Price T Rowe Associates Inc. MD raised its position in shares of Centessa Pharmaceuticals by 16.5% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 2,958,079 shares of the company’s stock valued at $33,427,000 after buying an additional 418,615 shares during the period. Nantahala Capital Management LLC acquired a new stake in shares of Centessa Pharmaceuticals during the 2nd quarter worth about $4,064,000. Driehaus Capital Management LLC raised its stake in shares of Centessa Pharmaceuticals by 89.5% in the 2nd quarter. Driehaus Capital Management LLC now owns 2,092,011 shares of the company’s stock valued at $18,891,000 after acquiring an additional 987,997 shares during the period. GSA Capital Partners LLP raised its position in Centessa Pharmaceuticals by 66.1% in the third quarter. GSA Capital Partners LLP now owns 93,658 shares of the company’s stock valued at $1,498,000 after purchasing an additional 37,275 shares during the period. Finally, First Light Asset Management LLC lifted its stake in Centessa Pharmaceuticals by 59.2% during the second quarter. First Light Asset Management LLC now owns 4,780,560 shares of the company’s stock worth $43,168,000 after purchasing an additional 1,778,515 shares in the last quarter. 82.01% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

Several equities analysts have issued reports on CNTA shares. B. Riley assumed coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They set a “buy” rating and a $33.00 price objective on the stock. BMO Capital Markets raised their price target on shares of Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research note on Monday, September 16th. Guggenheim boosted their price objective on Centessa Pharmaceuticals from $24.00 to $28.00 and gave the stock a “buy” rating in a research note on Friday, November 15th. Morgan Stanley raised Centessa Pharmaceuticals from an “equal weight” rating to an “overweight” rating and lifted their price target for the stock from $11.00 to $26.00 in a research note on Thursday, September 19th. Finally, Jefferies Financial Group increased their price objective on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the company a “buy” rating in a research note on Wednesday, September 11th. Six investment analysts have rated the stock with a buy rating, According to MarketBeat.com, the stock presently has a consensus rating of “Buy” and an average price target of $25.83.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.